NASDAQ:ADGI Adagio Therapeutics (ADGI) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free ADGI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$3.40▼$4.7852-Week Range N/AVolume22,357 shsAverage Volume2.27 million shsMarket Capitalization$504.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Adagio Therapeutics alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Adagio Therapeutics Stock (NASDAQ:ADGI)Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" ADGI Stock News HeadlinesNovember 9, 2023 | msn.comAdagio Therapeutics GAAP EPS of -$0.36 beats by $0.15October 10, 2023 | nytimes.comOur Favorite Advent CalendarsApril 25, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.August 11, 2023 | msn.comAdagio Therapeutics GAAP EPS of -$0.46 misses by $0.11April 3, 2023 | benzinga.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the FirmMarch 30, 2023 | markets.businessinsider.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the FirmMarch 3, 2023 | benzinga.comFILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGIFebruary 9, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIApril 25, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.January 25, 2023 | finance.yahoo.comForm 8.3 - Horizon Therapeutics PlcDecember 19, 2022 | benzinga.comInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopOctober 17, 2022 | bizjournals.comAdagio Therapeutics, now Invivyd, retools its strategy after losing two executivesSeptember 15, 2022 | finanznachrichten.deAdagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to InvivydSeptember 12, 2022 | tmcnet.comInvivyd Announces Multiple Next Generation COVID-19 AntibodySeptember 12, 2022 | finance.yahoo.comInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsAugust 22, 2022 | 247wallst.comHedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%August 17, 2022 | seekingalpha.comAdagio Therapeutics GAAP EPS of -$0.47August 15, 2022 | finance.yahoo.comAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsJuly 6, 2022 | finance.yahoo.comIs Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?July 5, 2022 | nasdaq.comAdagio Elevates Interim Chief Executive David Hering To Permanent CEOJuly 5, 2022 | finance.yahoo.comMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignJuly 5, 2022 | finance.yahoo.comAdagio Announces David Hering Named Permanent Chief Executive Officer and DirectorJuly 2, 2022 | benzinga.com(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson FistelMay 13, 2022 | investing.comAdagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2MMay 13, 2022 | finance.yahoo.comAdagio Therapeutics Reports First Quarter 2022 Financial ResultsApril 14, 2022 | seekingalpha.comAdagio stock falls after pausing filing plans for COVID therapy with FDAApril 14, 2022 | finance.yahoo.comAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA RequestSee More Headlines Receive ADGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADGI CUSIPN/A CIK1832038 Webadagiotx.com Phone603-252-2274FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.14% Return on Assets-50.28% Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.02 per share Price / BookN/AMiscellaneous Outstanding Shares108,831,000Free FloatN/AMarket Cap$504.98 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. David Hering M.B.A. (Age 46)CEO & Director Comp: $453.76kMs. Jill Andersen J.D. (Age 49)Chief Legal Officer & Corp. Sec. Comp: $580.12kMs. Laura Walker Ph.D. (Age 37)Co-Founder & Chief Scientific Officer Ms. Jane Pritchett V. Henderson (Age 56)CFO, Chief Bus. Officer & Treasurer Dr. Rebecca Dabora Ph.D. (Age 62)Chief Technology & Manufacturing Officer Dr. Elham Hershberger Pharm.D. (Age 54)Chief Devel. Officer Mr. Eric W. Kimble M.B.A. (Age 54)Chief Commercial Officer Mr. Ed CampanaroSr. VP of Clinical OperationsMore ExecutivesKey CompetitorsExscientiaNASDAQ:EXAIAlectorNASDAQ:ALECFate TherapeuticsNASDAQ:FATEC4 TherapeuticsNASDAQ:CCCCEditas MedicineNASDAQ:EDITView All Competitors ADGI Stock Analysis - Frequently Asked Questions How were Adagio Therapeutics' earnings last quarter? Adagio Therapeutics, Inc. (NASDAQ:ADGI) released its quarterly earnings data on Sunday, November, 14th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.24. When did Adagio Therapeutics IPO? Adagio Therapeutics (ADGI) raised $301 million in an IPO on Friday, August 6th 2021. The company issued 17,700,000 shares at $16.00-$18.00 per share. This page (NASDAQ:ADGI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
